ImmunityBio, Inc. IBRX Reportable Segment — Equipment, depreciation, and facility costs

Similar metrics at other companies

ZGReportable Segments — Facility expenses

$6M-14.3%

MXLReportable Segment — Cost, Depreciation and Amortization

$4.02M-10.0%

CWANReportable Segment — Facilities expense

$7.27M+91.4%

CDNSReportable Segment — Facilities and other infrastructure costs

$54.96M+25.4%

MDGLReportable Segment — Facility And Other Expenses

$27.61M+74.9%

PRAXReportable Segment — Depreciation expense

$39K-17.0%

Questions, answered.

What is ImmunityBio, Inc.'s reportable segment — equipment, depreciation, and facility costs?

ImmunityBio, Inc. (IBRX) reported reportable segment — equipment, depreciation, and facility costs of $13.59M in Q1 2026.

How has ImmunityBio, Inc.'s reportable segment — equipment, depreciation, and facility costs changed year-over-year?

ImmunityBio, Inc.'s reportable segment — equipment, depreciation, and facility costs increased by 3.0% year-over-year, from $13.19M to $13.59M.

What is the long-term trend for ImmunityBio, Inc.'s reportable segment — equipment, depreciation, and facility costs?

Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — equipment, depreciation, and facility costs has grown at a 0.3% compound annual growth rate (CAGR), from $51.81M to $52.09M.

What does reportable segment — equipment, depreciation, and facility costs mean?

Represents the allocated costs for the use of physical assets, including depreciation of laboratory equipment and facility lease expenses. These are the fixed overhead costs required to maintain the segment's operational infrastructure.